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Nanoparticles have recently been developed for application as drug carriers in different 
fields, including biomedical engineering. This study was focused on the use of a millifluidic chip 
for synthesis of polymeric poly (lactic co-glycolic acid) (PLGA) nanoparticles and the 
understanding of PLGA nanoparticles interaction and effect on red blood cells (RBCs). A method 
for nanoparticles synthesis on a millifluidic chip was developed, exploiting the precise flow control 
offered by this device. PLGA nanoparticles ranging from 230nm to 350nm in diameter were 
produced. Smaller nanoparticles of lower polydispersity were synthesized at higher flow rates of 
the aqueous phase; increase in the ratio of aqueous phase to organic phase also decreased the size 
of the nanoparticles prepared. 
The interaction of the PLGA nanoparticles synthesized with the millifluidic chip with 
RBCs was visualized using a scanning electron microscope and quantified by flow cytometry. The 
effect of PLGA nanoparticles on RBCs integrity was studied by a hemolysis assay. Results 
indicated that PLGA nanoparticles adhered to the surface of red blood cells, but had no significant 




CHAPTER 1. INTRODUCTION 
1.1 General Background 
1.1.1 Nanoparticles 
Nanoparticles are solid spherical structures ranging between 1 to 100 nm in size [1]  
researched extensively as drug delivery systems for drug molecules and macromolecules, such as 
nucleic acids, proteins, and hormones [2]. Also, a wide variety of small hydrophilic drugs, 
hydrophobic drugs, vaccines, and biological macromolecules can be delivered using nanoparticles 
[3, 4]. Due to the enhanced permeability and retention effect, nanoparticles can be used to target 
specific organs, or tumor cells [5]. Biodegradability and biocompatibility is a basic requirement 
for their use in the biomedical field. Polymeric nanoparticles among all, have garnered 
extraordinary importance for the development of drug delivery system  as ideal carriers due to 
their controllable characteristics, their ability to entrap, dissolve, or target drugs [6], and their 
ability to easily interface with biological systems. 
Poly (lactic-co-glycolic) acid (PLGA) (Fig 1.1) is a polymer most successfully used in 
nanoparticle synthesis for biomedical applications. PLGA is US FDA and European Medicine 
Agency (EMA) approved for various drug delivery systems in humans [7]. PLGA is known for its 
biocompatibility and ability to resorb through natural pathways. The hydrolysis of PLGA leads to 
lactic acid and glycolic acid, the metabolite monomers [1] are easily metabolized by the body and 
hence minimum systemic toxicity risk is associated with PLGA for drug delivery or biomaterial 
applications.  
 




PLGA based nanoparticles present many advantages for drug delivery. They are used in 
protecting drugs from degradation, enhancing their stability, encapsulating hydrophobic and 
hydrophilic drugs depending on the method of preparation, and can be formulated for targeted 
delivery [1] for treatment of various diseases [8]. PLGA nanodelivery systems can be administered 
by different routes (orally, by inhalation, by injection, etc.). Regardless of the delivery route, due 
to their small size, these nanoparticles are able to translocate to the circulatory system with 
unknown effects on the blood’s components.  
1.1.2 Millifluidics 
 Millifluidics is a scaled-up version of microfluidics. In microfluidics, a set of micro-
channels etched or molded into a material forming a microfluidic chip are connected together to 
achieve a desired function of mixing, redirecting, or reactions in the cell [9]. These microfluidic 
systems have been used as lab-on-a-chip devices in a wide range of applications, from preparation 
of materials to observation of the particles mixing and reaction [10]. Due to the ability of 
manipulation of extremely small amounts of reagents, these systems have emerged as an 
innovative approach for providing precise control of mixing and physical processes at microscales. 
The increased speed of analysis, parallel screening, well defined and repeatable conditions, and 
lower cost of research, make microreactors attractive options to the study of the nanoparticle 
interaction [9]. 
 The hydrodynamic features in millifluidics are bigger than those of microfluidic systems, 
but similar control over the fluid flows can be provided even at this scale. Furthermore, 
millifluidics chips can be easily manufactured and rapidly assembled-disassembled as per need. 
Microfluidic reactor systems have been used by different groups for the controlled synthesis of 




various shapes, dimensions, and compositions were synthesized in a millifluidic based reactor [14]. 
Biswas et al (2012) demonstrated that chip-based millifluidic systems can be utilized for the 
synthesis of ultra-small copper nanoclusters [10] and gold nanoparticles [15]. Li et al (2012) used 
it for the in situ characterization of the size, evolution, and growth of gold nanoparticles [16]. 
Millifluidic chips provided for the opportunity for in situ characterization as well. When coupled 
with other characterization techniques for the real-time analysis of the reactions taking place, 
millifluidic chips were successfully used to visualize the interaction between chemicals [9].  
 Studies have already been reported on the use of millifluidic devices for the synthesis of 
inorganic Nanoparticles, but never used for synthesis of PLGA nanoparticles. This study focused 
on the use of millifluidic chips as the platform for the synthesis of PLGA nanoparticles.  
1.1.3 NP-RBCs interaction 
A few studies have been published on the compatibility of PLGA nanoparticles in general 
[1, 3, 7, 17], and very few on PLGA nanoparticles’ interaction and impact on red blood cells [6, 
17, 18]. One such study focused on the measurement of red blood cell damage and blood clotting 
in the presence of PLGA nanoparticles, and surfactant stabilized PLGA at the nanoparticle 
concentration of 1 and 10% weight by volume. Hemolytic testing and thromobloelastograph 
analysis were used to understand the interaction of particles with blood constituents [8]. Another 
group studied lysis of erythrocytes when exposed to nanoparticles made from PLGA conjugated 
with alendronate (PLGA-ALE nanoparticles). Hemolysis induced by different concentration of 
PLGA-ALE nanoparticles ranging between 5.6ng/ml to 560µg/ml was tested [19]. Biomimetic 
mucin modified PLGA nanoparticles were evaluated for hemocompatibilty and cellular uptake by 
Thasneem et al (2013). PLGA nanoparticles interaction with plasma proteins and blood 




modified PLGA nanoparticles were incubated with 100µl of RBCs at 37oC for 30min. Results 
showed that all blood components were compatible to PLGA and modified nanoparticles and 
hemolytic effect were far below the permissible hemolysis level [20]. Another study reported on 
the interaction of PLGA nanoparticles with blood components at a low 3mg/ml nanoparticle 
concentration. Interaction of nanoparticles with proteins, coagulation cascade, and hemolytic 
character were studied. Furthermore, the integrity of erythrocytes were evaluated by microscopic 
observation [18].  
The present study was designed to fill in the gap on the concentration-dependent interaction 
of PLGA nanoparticles and their effect on red blood cells. PLGA nanoparticles stabilized with 
poly vinyl alcohol (PVA) surfactant were synthesized with a novel millifluidcs device and NP-
RBCs interaction was quantified by measuring NP-RBC association and effect on RBC hemolysis.  
1.2 Objectives 
The goal of the present research was to develop a method for synthesis of PLGA 
nanoparticles on a millifluidic platform and to use these particles to study nanoparticles interaction 
with red blood cells. PLGA nanoparticles synthesized using the millifluidic chip were 
characterized by light scattering techniques and electron microscopy and the method developed 
was optimized for synthesis of nanoparticles of similar size to control nanoparticles made using 
the nanoprecipitation using a bulk method. The study of the interaction between the nanoparticles 
and the blood cells was performed by evaluating the nanoparticles association with red blood cells 
by flow cytometry and scanning electron microscopy; the effect of nanoparticles on red blood cells 
was assessed by measuring RBC hemolysis. Specifically, the following objectives were set: 
1) Develop and optimize method for synthesis of PLGA nanoparticles using a millifluidic chip, 




scattering and transmission electron microscopy were used to characterize the nanoparticles 
prepared. 
2) Study nanoparticles interaction with red blood cells (RBCs). Fluorescently-tagged 
nanoparticles were used to visually assess NP-RBC interaction. Quantification was done by 
flow cytometry. Adhesion of the nanoparticles with the red blood cell was visualized by 
scanning electron microscopy (SEM). 
3) Quantify effect of nanoparticles on RBCs. The effect of nanoparticles on the integrity of the 
RBCs membrane was assessed by measuring RBC hemolysis.  
1.3 Significance 
 PLGA nanoparticles can be synthesized using different techniques. The characteristics of 
the nanoparticles prepared depends upon the techniques and parameters used. Millifluidic chips, 
which have been used as the platform for the chemical reaction and synthesis of metallic and non-
metallic nanoparticles, has not been previously reported for synthesis of PLGA nanoparticles.  
Furthermore, the effects of the nanoparticles on the RBCs is a major concern since 
nanoparticles that can access the circulatory system might be cytotoxic. Many studies have been 
conducted on the interaction of metallic and non-metallic nanoparticles with blood constituents, 
but comparatively fewer studies have been done on the interaction of polymeric PLGA 
nanoparticles with RBCs. This study focuses on the concentration-dependent interaction of PLGA 
nanoparticles stabilized with poly-vinyl alcohol (PVA) with rat RBCs. 
1.4 Thesis Organization 
 The thesis includes a total of four chapters. The present chapter provides general 
background on PLGA nanoparticles, millifluidic chips, the objectives, and the significance of the 




The second chapter describes the use of millifluidic chips for the synthesis of PLGA 
nanoparticles. The third chapter discusses the association, interaction, and effects of PLGA 
nanoparticles prepared in millifluidic chips with rat RBCs. The thesis closes with the fourth chapter 
that includes conclusions and future work. 
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CHAPTER 2.  POLY (LACTIC-CO-GLYCOLIC ACID) NANOPARTICLE SYNTHESIS 
USING A MILLIFLUIDIC CHIP 
 
2.1 Introduction 
 Poly (lactic-co-glycolic acid) (PLGA) is one of the most frequently used synthetic 
copolymers, known for its biocompatibility and biodegradability [1], approved by the US Food 
and Drug Administration (FDA) for drug delivery and therapeutic application [2]. PLGA particles 
have been widely used as delivery agents for different drugs, peptides, proteins, DNA, viruses, and 
antibacterial antigens [3].  
There are many different techinques of synthesizing PLGA nanoparticles. The size and size 
distribution of the PLGA nanoparticles are affected by the technique and parameters used for the 
synthesis of particles. Synthesis parameters such as PLGA molecular weight, surfactants, and other 
additives are directly responsible for the physical characteristics of the particles [4]. In general, 
methods available for PLGA nanoparticles synthesis can be divided into two classes: bottom-up 
and top-down techniques. In the bottom-up techniques, such as emulsion polymerization, 
interfacial polymerization, and precipitation polymerization, a monomer is established as a starting 
point,  whereas in top-down techniques such as emulsion evaporation, emulsion diffusion, solvent 
displacement, and salting out, the nanoparticles are synthesized from the pre-formed polymers [4].  
Emulsion diffusion, solvent evaporation, and solvent displacement (or nanoprecipitation) 
are common top-down synthesis techniques. In the emulsion diffusion method, the polymer 
(PLGA) is dissolved in an organic solvent (e.g., benzyl alcohol, propylene carbonate, ethyl 
acetate), which is partially miscible in water. The organic phase is mixed with an aqueous solution 
of suitable surfactant under stirring. The formation of nanoparticles is a result of the diffusion of 
the organic solvent in water and the interfacial turbulence generated during diffusion [5]. Emulsion 




requiring large amounts of water for nanoparticle formation and a substantial amount of time is 
required for emulsion agitation [4]. The solvent evaporation method is based on the emulsification 
of an organic solution of the polymer in an aqueous phase followed by the evaporation of the 
organic solvent, non-soluble in water as follows. The polymer is dissolved in a suitable organic 
solvent. The prepared organic phase is poured into the aqueous phase and the emulsification is 
carried out under high-shear stress to reduce the size of nanoparticles. The process of 
emulsification is then followed by the evaporation of the organic solvent under a vacuum, which 
leads to the nanoparticles formation. The use of non-highly-toxic solvents and additives used for 
nanoparticles size reduction are its advantages, but its disadvantage is high consumption of energy 
due to the need of high stress shear for the reduction of emulsion droplet [6].  
The nanoprecipitation (solvent displacement) method is another method in which the 
nanoparticles are formed instanteously by rapid solvent diffusion. The method was developed by 
Fessi and coworkers, to form nanoparticles in the range of 100-300 nm [7]. In this method, PLGA 
polymer is dissolved in a polar, water-miscible solvent and the solvent is poured into the aqueous 
solution with surfactant in a controlled manner. Although this technique requires highly soluble 
polar solvents, it uses non-highly-toxic solvents commonly found in research labs, and has a low 
energy consumption.  
The nanoprecipitation method has not been limited to the fabrication of PLGA 
nanoparticles [8]. It was also used for encapsulation of hydrophilic and lipophilic drugs [9, 10], 
synthesis of DNA-loaded [11], and functionalized protein [12-14] nanoparticles. In the study by 
Jose et al (1999), PLGA nanoparticles in the range of 160-170nm, with a relatively narrow particle 
size distribution were formed [10]. nanoparticles of 155-210nm diameter and -49 to -55mV zeta 




In another study, DNA-loaded PLGA nanoparticles were fabricated by the 
nanoprecipitation technique; the method yielded uniform spherical shaped particles with an 
average particle size near 200nm and negative zeta potential of -12.6mV [11]. Spherical particles 
with an average particle size of 230nm and zeta-potential of -45mV were prepared by Betancourt 
(2007). These nanoparticles were found to be able to control the release of doxorubicin in a pH-
dependent manner and effectively deliver drugs to breast cancer cells [16]. Rivastigimine-loaded 
PLGA nanoparticles of a minimum particle size of 135.6 ±4.2nm were prepared by Joshi et el in 
2010 [17]. Protein functionalized tramadol-loaded PLGA nanoparticles of a particle size of less 
than 150nm and an entrapment efficiency greater than 70% have been prepared as per reported by 
Lalani et al (2013) [12]. The nanoprecipitation method has been used to synthesize PLGA-PVP-
pluronic nanoparticles with a diameter of less than 300nm and zeta potentials of -18.99mV as 
reported by Shakeri et al (2015) [14].  
 Nanoprecipitation techniques have been modified with time. The ability to control the 
mixing processes required for the synthesis of nanoparticles, resulting in variable nanoparticles 
physiochemical properties, has been researched and is progressing. Microfluidic and millifluidic 
systems, which have emerged as an important tool for different chemical and biological 
applications, have been an attractive technology adopted in the nanoparticles synthesis. The 
convergence and integration of microfluidic and millifluidic systems with particle technologies 
has shown considerable progress lately for the development of microparticles and nanoparticles 
[18]. Typical (i.e. bulk) nanoprecipitation technique involve dropwise addition of the organic 
phase into the larger aqueous phase. The better control over mixing of microfluidic/millifluidic 




Karnik et al (2008) demonstrated the use of the microfluidic channels in nanoparticle 
synthesis by rapidly mixing polymer-acetonitrile solutions and water to synthesize PLGA-PEG 
nanoparticles with diameters in the range of 10-50nm. The mixing time was varied by changing 
the flow ratio of water and acetonitrile streams and nanoparticles prepared with this optimized 
method  were smaller than 30-35nm in size compared to nanoparticles formed by regular bulk 
nanoprecipitations method [18]. A Fluidic Nanoprecipitation System constructed with an inlet 
channel inserted into the center of a dispersing channel (3/32”) was used by Xie and group to 
fabricate the highly uniform PLGA particles with diameters in the range of 140-500nm [8]. A 
semicircular microfluidic tubing method was developed by Wang and group to synthesize size 
controlled PLGA nanoparticles ranging from 55 to 135nm in diameter. The microfluidic device 
allowed for a total flow rate of 410ml/h. It was reported that nanoparticles produced at a high flow 
rate were smaller in comparision to those produced at a lower flow rate [19]. Lim et al (2013) 
reported the parallel 3D hydrodynamic flow focusing device using a multilayer microfluidic 
system, and synthesized PLGA-PEG nanoparticles within the range of sizes (13-150 nm) [20]. 
These studies have demonstrated the succesful use of microfluidic platform for the synthesis of 
PLGA nanoparticles. Engl et al (2005) demonstrated the use of a tubular millifluidic reactor to 
synthesize monodisperse particles. The particle sizes produced were reported to be much larger 
than those obtained with microfluidic devices (100µm to 3mm compared to 20µm to 200µm) [21]. 
Millifluidic chips have not been used to prepare particles in the nanometer range. This research 
focused on synthesis of PLGA nanoparticles using a millifludic chip by nanoprecipitation and 
optimizing the method to obtain smallest nanoparticles size, in the 200-300 nm range. The goal of 




make use of the nanoprecipitation technique for the synthesis of PLGA particles of a controllable 
sizes similar to those obtained by bulk methods.  
2.2 Materials and Methods 
2.2.1 Materials 
  Poly (D, L –lactide-co-glycolide) acid (PLGA), poly vinyl alcohol (PVA), chitosan, 
acetone, and acetonitrile were purchased from Sigma-Aldrich (Sigma Chemical Co.Ltd., St. Louis, 
MO). Nanopure water was obtained using a Nanopure Diamond System (Barnstead international, 
IA, USA). All other reagents and components used in this study were analytical grade.  
The Nemesys syringe pump used for controlling the flow rate of the organic and aqueous 
phases was purchased from Cetoni GmbH (Gewerbegebiet Korbwiesen, Korbussen, Germany) and 
the millifluidic chip was fabricated in the J. Bennett Johnston Sr. Center for Advanced 
Microstructures & Devices (CAMD LSU). 
 The millifluidic chip used in the study was prepared from a polyvinyldene fluoride (PVDF) 
polymer, which is a silicon-based organic polymer and, in general, inert, non-toxic and non-
flammable. The millifluidic chip used in this study consisted of a serpentine channel with the 
dimensions of 2mm (W) x 0.15 mm (H) x 220 mm (L) (Figure 2.1). This chip had two inlets and 
a single outlet which can be connected with the syringe pump using the manifold. The flow rates 
of the solution were controlled by Nemesys UserInterface software.  
a.    b.  
Figure 2.1. Schematic representation of the millifluidic chip with 2mm (W) x 0.15mm (H) x 




2.2.2 Experimental Set-up 
 In this study, nano-precipitation has been applied to synthesize PLGA particles using a 
millifluidic chip, in three steps. First, the polymer (20mg/ml) was dissolved in a suitable organic 
solvent (organic phase: acetone and acetonitrile) and the surfactant (PVA) were dissolved in water 
at 2% (aqueous phase). Acetone and acetonitrile were chosen as they dissolve PLGA, are miscible 
in water, and do not affect the PVDF chip. In addition, they evaporate in room temperature. PVA 
was chosen as the surfactant since it is commonly used to prepare PLGA nanoparticles for 
biomedical applications. In the second step, the organic phase and aqueous phase were pumped 
through the channel of a millifluidic chip using the Nemesys pump, where they interacted with 
each other. Lastly, the solvent was evaporated and the particles were collected in suspension.  
 The Nemesys syringe pump was used to control the flow rate of the organic phase and 
aqueous phases in the millifluidic chip. Depending upon the flow rate controlled by neMESYS 
UserInterface (Cetoni GmbH, Korbusen, Germany), the Nemesys syringe pump started to flow the 
two solutions into the millifluidic chip where the organic phase and aqueous phase interacted  with 
each other within the snake channel. The resulting suspension was collected at the outlet and then 
placed in the rotavap, in order to evaporate the organic solvent. Varying flow rate ratios (aqueous 
phase to organic phase) were maintained, as follows: 10:1, 20:1, 30:1, and 40:1 v/v. The flow rate 
of the aqueous phase was kept constant and the flow rate of the organic phase was manipulated to 
get achieve desired flow rate ratios of aqueous phase to organic phase. For example, if the flow 
rate of the aqueous phase was 600µl/min, the flow rate of the organic phase was maintained at 
60µl/min, 30µl/min, 20µl/min, and 15µl/min to get the desired flow rate ratio. Similar flow rate 




 PLGA nanoparticles were prepared by the conventional bulk nanoprecipitation method 
[19], and their characteristics compared against PLGA nanoparticles synthesized using the 
millifluidic chip. The organic phase (500µl, 250µl, 167µl, 125µl) with a PLGA concentration of 
20mg/ml in acetone/acetonitrile was added drop-wise into four vials containing 5ml of the aqueous 
phase to maintain the aqueous phase to organic phase ratio (10:1, 20:1, 30:1 and 40:1 v/v); the 
emulsion was stirred for 3min at room temperature and left to evaporate at room temperature.  
2.2.3 Characterization of PLGA Nanoparticles 
 Particle size (hydrodynamic diameter), polydispersity index (PDI) and zeta potential of the 
PLGA nanoparticles were determined by dynamic light scattering (Malvern Zetasizer Nano ZS, 
Malvern Instruments Ltd, Worcestershire, UK).  A volume of 1ml of the solution was taken in 
disposable folded capillary cells suitable for light scattering and loaded into the Zetasizer for size 
and zeta potential measurement.  
2.2.4 Morphology Analysis 
 The morphology of the freshly prepared nanoparticles using millifluidic chip was done by 
JEOL JEM1400 Transmission Electron Microscopy (TEM), (JEOL USA. Inc., MA, USA). A 
copper grid of 400 mesh with carbon film was glow discharged. One droplet of the freshly prepared 
PLGA nanoparticles sample was placed on a copper grid of 400 mesh with a carbon film. Uranyl 
acetate was used to improve the contrast of the sample. The excess sample was removed with a 
filter paper and the sample on the grid was dried for 10 min at room temperature before being 




2.3 Results and Discussion 
2.3.1 DLS Characterization 
PLGA nanoparticles were synthesized at different flow rates with PVA as the surfactant at 
varying flow rate ratios for the water:organic phase (10:1, 20:1, 30:1 and 40:1 v/v). The size, 
polydispersity, and zeta potential were measured to compare characteristics of the particles 
synthesized by the millifluidic device with those made using a conventional bulk nanoprecipitation 
technique for two solvents, acetonitrile (Table 2.1) and acetone (Table 2.2). The DLS results of 
the samples indicated that PLGA nanoparticles of approximately 200-220nm and PDI between 
0.15-0.2 were precipitated using the conventional bulk method regardless of the solvent used.  
Table 2.1: Comparison of size, size distribution, PDI, and zeta potential of smallest nanoparticles 
prepared using the conventional bulk method and millifluidic chip at different flow rates. 
Acetonitrile was used as the organic phase. 
Method Nanoparticle Minimum Size 
(nm) 
PdI Zeta Potential 
(mV) 
Bulk PLGA 198.43 ± 0.95 0.108 ± 0.02 -9.71 ± 0.75 
Millifluidic Chip 
(600µl/min) 
PLGA 248.3 ± 3.08 0.25 ± 0.01 -10.03 ± 0.59 
Millifluidic Chip 
(1000µl/min) 
PLGA 196.93 ± 14.30 0.199 ± 0.028 -11.67 ± 0.20 
 
PLGA nanoparticles prepared with acetonitrile by the conventional method measured 
approximately 200nm in diameter and had a narrow size distribution between 0.15-0.18 (Table 
2.1). The minimum average size of nanoparticles synthesized using the millifluidic chip at different 
flow rates with the same solvent was larger than the nanoparticles prepared with the bulk method, 
but in a similar range. The average size of PLGA nanoparticles at lower flow rate (600µl/min) was 
248.3±3.08nm, and at higher flow rate (1000µl/min), the average size was 196.93±14.30nm for 




millifluidic chip was above 0.2. PLGA nanoparticles were negatively charged (-10mV) (Table 
2.1).   
PLGA nanoparticles of a minimum size of approximately 200nm and with polydispersity 
index between 0.14-0.18 were synthesized using acetone by the conventional bulk method (Table 
2.2). The minimum size of nanoparticles synthesized using the millifluidic chip at different flow 
rates was larger than that of the nanoparticles prepared with the bulk method, but in a similar range. 
The average size of PLGA nanoparticles at lower flow rate (600µl/min) was 238.5±4.17nm and at 
higher flow rate (1000µl/min) was 217.7±2.37nm. PDI indicated that the size of PLGA 
nanoparticles was more widely distributed (PDI>0.2) than the nanoparticles synthesized using 
conventional method. PLGA nanoparticles were negatively charged for all the experiments.  
PLGA nanoparticles had zeta potential of nearly -9.0 mV. Average size of PLGA nanoparticles 
decreased with increase in the flow rate (Table 2.2). 
Table 2.2: Comparison of size, size distribution, PDI, and zeta potential of smallest nanoparticles 
prepared by conventional bulk method and millifluidic chip at different flow rates. Acetone was 
used as the organic phase. 
Method Nanoparticle Minimum Size 
(nm) 
PdI Zeta (mV) 
Bulk PLGA 197.70 ± 2.74 0.174 ± 0.023 -9.2 ± 0.75 
Millifluidic Chip 
(600µl/min) 
PLGA 238.5 ± 4.17 0.252 ± 0.022 -8.86 ± 0.41 
Millifluidic Chip 
(1000µl/min) 
PLGA 217.7 ± 2.37 0.221 ± 0.007 -8.57 ± 0.60 
 
PLGA nanoparticles synthesized at a higher flow rates (1000µl/min) and FRR of 40 (flow 
rate of aqueous phase to organic phase was 40:1 v/v) were close to the size of nanoparticles 
synthesized using the bulk method at that ratio (Figure 2.2). Smaller sized nanoparticles were 
prepared at a higher flow rate of aqueous phase (1000µl/min) and higher FRR. Polydispersity was 





a.    
b.   
Figure 2.2:  Size of PLGA nanoparticles (a and b) as a function of flow rate ratios. Different 
solvents as follows: PLGA nanoparticles prepared with acetonitrile as organic solvent (a) PLGA 
nanoparticles prepared with acetone as solvent (b) 
 PLGA nanoparticles of approximately 220nm were obtained at a higher flow rate 
(1000µl/min) and a large FRR (aqueous phase to organic phase is 40:1 v/v) for different solvent 
used (Table 2.1 and Table 2.2). The size of the nanoparticles decreased as FRR increased. When 











































approximately 252.8±14.89nm were synthesized for the particles with acetonitrile as the organic 
phase and nanoparticles of size approximately 217.7±12.35nm were obtained for the particles with 
acetone as the organic phase. PLGA nanoparticles synthesized at a low flow rate of the aqueous 
phase (600µl/min) with FRRs of 10, 20, 30, and 40 were also characterized. The sizes of the PLGA 
nanoparticles were 266.7nm at FRR 10, which decreased to 238.4nm at FRR 40 for particles 
prepared from acetonitrile as the organic phase. At the same FRRs, the nanoparticles obtained at 
higher flow rate (1000µl/min) for the same approach were approximately 220nm, which was 50nm 
smaller than those at the lower flow rate (600µl/min) (Figure 2.2). 
2.3.2 Morphological Analysis 
 TEM image for the PLGA nanoparticles prepared in conventional bulk method (Figure 
2.3a) and millifluidic synthesized nanoparticles (Figure 2.3b and c) confirmed the DLS data. The 
size of the PLGA nanoparticles analyzed by TEM shows an average size of 200nm with a size 
distribution between 170nm to 250nm for the bulk-synthesis nanoparticles and between 190nm to 
400nm for the PLGA nanoparticles stabilized with PVA surfactant for the nanoparticles prepared 
at a lower flow rate and FRR 10 using acetonitrile as the organic solvent in the millifluidic device. 
The TEM images of the PLGA nanoparticles formed at a flow rate of 1000µl/min and FRR 40 
showed a good distribution and a size distribution of the nanoparticles between 220nm to 270nm. 
Presence of smaller micelles are also evident in the TEM images (Figure 2.3c).  
In this study, PLGA nanoparticles were synthesized using a conventional bulk method and 
the method was adapted to make nanoparticles on a millifluidic chip under different conditions. It 
was evident from the DLS characterization and TEM image that nanoparticles of smaller size and 




Nanoparticles synthesized at higher flow rate and FRR were only 20nm larger than the 
nanoparticles prepared in bulk process and had similar zeta potential. 
a.   b.   c.  
Figure 2.3: PLGA Nanoparticles prepared by bulk nanoprecipitation (a) and synthesized by 
millifluidic chip at lower flow rate (600µl/min) and FRR 10 (b) and at higher flow rate 
(1000µl/min) and FRR 40 (c).  
  As stated in the work done by Wang and group (2014), smaller particles than those 
prepared in bulk method (200nm) were synthesized in a microfluidic device. Using the 
microfluidic channel of cross section 50µm x 50µm, at the flow rate of 41ml/h (683µl/min), 
particles of minimum size of 110nm were prepared; at the flow rate of 410ml/h (6833µl/min), the 
particles synthesized were smaller. The higher flow rate resulted in enhanced convective mixing 
which was responsible for precipitation of small sized particles [19]. With the millifluidic chip 
used in our study, the maximum possible flow rate was 1000µl/min. Further, the width of the chip 
was 2mm thus the droplet size formation and the time taken while passing through the inlet at 
different flow rate ratio also contributed toward the formation of larger particles compared to 
particles prepared in the tubing method. All samples were collected and no dialysis was performed 
to remove the excess surfactant, which formed smaller micelles as seen in the TEM image. Engl 
(2007) used a similar, but tubular millifluidic devices made of glass capillaries to synthesize 
particle in the range of 100µm to 3mm [21] whereas, in our study, particles were formed in the 




The size of PLGA nanoparticles was 200nm for higher flow rate for acetonitrile as organic 
phase but PLGA nanoparticles were 20nm larger when acetone was used as organic phase. 
Difference in the organic phase (acetonitrile versus acetone), did not have a big impact on the 
average size of the particles. Particle size were similar for each case (250nm for lower flow rate 
and 210nm for higher flow rate for PLGA nanoparticles).  
2.4 Conclusions and Future Works 
Different methods have been developed to synthesize PLGA nanoparticles, starting from 
preformed polymers, each with their own advantages and disadvantages. Nanoprecipitation 
method which is based on rapid solvent diffusion for particle synthesis has been explored in this 
work for the synthesis of nanoparticles in a millifluidic device. Flow rate and FRR played a critical 
role in controlling the size of nanoparticles prepared, whereas organic solvent had a smaller impact. 
Nanoparticles with an average size of 220nm and narrow size distribution similar to those 
formed by conventional bulk synthesis method were synthesized in a millifluidic chip. The average 
size of the nanoparticles decreased with an increment in FRR of aqueous phase to organic phase. 
At a lower flow rate, the PDI was around 0.25, whereas the PDI was close to 0.2 at higher FRR. 
PDI of all the nanoparticles decreased for the higher FRR. TEM images supported the findings 
that at a lower flow rate and FRR 10, size distribution was higher compared to nanoparticles 
formed at a higher flow rate and FRR of 40. 
While this work has demonstrated the possibility of utilizing the millifluidic chip for 
synthesizing the nanoparticles, further work needs to be done on the synthesis of nanoparticles at 
higher flow rate to allow for synthesis of smaller nanoparticles. Further studies should be 
conducted on the effects of other different surfactants and solvents on formation of various 
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CHAPTER 3.  CONCENTRATION-DEPENDENT INTERACTION OF POLY (LACTIC-
CO-GLYCOLIC) ACID NANOPARTICLES WITH RED BLOOD CELLS: 
ASSOCIATION AND EFFECT ON RBC HEMOLYSIS 
 
3.1 Introduction 
 The application of nanotechnology in medicine, specifically in drug delivery is spreading 
rapidly, with the hope that it will bring significant advances in the treatment of disease.  
Nanoparticles have unique chemical and physical properties which make them suitable carriers for 
a wide variety of hydrophobic, hydrophilic, small drugs, vaccines and biological macromolecules 
[1]. Nanoparticles can be delivered through different routes to the designated targets, but regardless 
of the delivery route, Nanoparticles are likely to end up in the circulatory system, where they will 
interact with blood constituents.  
 A number of studies have been published on the nanoparticles interaction with blood 
constituents. Different techniques such as Surface-enhanced Raman spectroscopy (SERS) [2], 
Transmission electron microscopy (TEM) [2-5], flow cytometry, and fluorescence microscopy [6] 
have been used to study the interaction and effects of the nanoparticles on blood constituents. Most 
of these studies were focused on inorganic nanoparticles. 
In the in vivo study conducted by Drescher et al (2013) [2], red blood cells were exposed 
to gold (Au) and silver (Ag) nanoparticles and the effect of the nanoparticle presence on hemolytic 
activity was determined by UV-VIS. Silver nanoparticles of 55±20nm at 2.0 x 10-11 M had a 
destructive effect on the membrane of red blood cells and red blood cells exposed to gold 
nanoparticles at 3.7x 10-11 M showed minimal changes [2]. In another study, red blood cells 
exposed to 100µg/ml Ag nanoparticles induced hemolysis, membrane damage and morphological 
alterations. It was reported that the hemolysis rate decreased with the agglomeration or increasing 




topography, hemagglutination induced by silver, gold and platinum nanoparticles on contact to 
RBCs has been studied, as well to confirm that silver nanoparticles were less biocompatible 
compared to other nanoparticles [7].  
Copper and Cu-Zn alloy nanoparticles damaged significantly the membrane of the red 
blood cells at the particle mass dose of 20µg/ml due to hemoglobin aggregation whereas CuO 
nanoparticles did not induced any hemolytic effects on red blood cells up to 1mg/ml [3]. Damage 
of the red blood cell membrane due to the copper based nanoparticles was also reported by Li 
(2013) in fish blood [8]. TiO2 and Zn based nanoparticles also adhered well to the membrane of 
RBCs, TiO2 causing RBCs aggregation and ZnO causing rupture of RBC membrane at the 
concentration of 1mg/ml [5]. Exposure of RBCs to TiO2 nanoparticles at the nanoparticle 
concentration of 100µg/ml indicated negative effects as TiO2 attached to RBC and caused 
hemolysis [9]. 
Concentration and size-dependent hemolytic effect were also reported for both nonporous 
and porous silica [10]. Mesoporous Silica nanoparticles were reported to have a low cytotoxic 
effect towards mammalian cells at concentrations below 100µg/ml [11]. Interaction of silicon 
based nanoparticles with blood cells showed the death of leukocytes [12], and also hemolysis of 
red blood cells [13]. Also, Tricalcium phosphate (TCP) and hydroxypatite nanoparticles (HAP) 
which are highly used in biomedical applications showed over 5% increment in hemolytic effect 
at 1mg/ml nanoparticle concentration [14]. Multi-walled carbon nanotubes (MWCNTs) were also 
shown to have a significant hemolytic activity against red blood cells [15]. 
Based on these studies, it was therefore established that while Au and platinum 
nanoparticles interacted with blood components without much effect, Ag nanoparticles caused cell 




blood cells [3, 8], Fe nanoparticles only influenced the physiology of RBCs [6], Si based 
nanoparticles also had adverse effects on the RBCs [10-13], and TiO2 nanoparticles [5, 9] and 
MWCNTs had negative impact on the RBCs as well. 
While the effect of inorganic nanoparticles such as those described above on red blood 
cells was extensively covered in the literature, only a limited number of studies were published on 
interaction of polymeric nanoparticles with blood constituents. Polymeric nanoparticles such as 
polystyrene nanoparticles (PS-NP), polymethacrylate nanoparticles (NP), PEGylated and non-
PEGylated copolymer conjugated nanoparticles and nanoparticles of complex polymeric 
structures, such as those made of poly(3-hydroxybutyrate)-poly(ethylene glycol)-poly(3-hydroxyl 
butyrate) (PHB-PEG-PHB), and chitosan-N-trimethylaminoethylmethacrylate chloride-PEG (CS-
M-PEG) copolymers have been reported  [15]. Polymethacrylate nanoparticles of average diameter 
of about 127nm were found to have minimal cytotoxicity [16]. Another research group focused on 
complex polymeric structure PHB-PEG-PHB, recorded no signs of cytotoxicity and hemotoxicity 
for nanoparticles of average size 72.6nm up to the concentration of 120µg/ml [17]. Another study 
focused on 240nm sized protein-encapsulated hydrophobic γ-PGA nanoparticles with -27mV zeta 
in PBS, demonstrated the hemolytic properties of nanoparticles when pH decreased from 7 to 5.5 
[18].  
A few studies only have been published on compatibility of PLGA nanoparticles in general, 
and even less so on PLGA nanoparticles interaction and impact on red blood cells. One such study 
focused on the measurement of red blood cell damage and blood clotting in the presence of PLGA 
nanoparticles and effect on the nanoparticles [19] to conclude that interaction between PLGA 
nanoparticles and blood constituents depended on particle type (raw PLGA, PEG-lyated PLGA 




hemolysis was caused by the surfactant stabilized PLGA particles compared to raw PLGA 
nanoparticles. The cytotoxic effect was reported to be significantly different for different particle 
type, as well. Another group studied lysis of erythrocytes when exposed to nanoparticles made 
from PLGA conjugated with alendronate (PLGA-ALE nanoparticles) at concentrations of 
560µg/ml, 56µg/ml and 5.6µg/ml. Results obtained from the study showed that PLGA-ALE 
nanoparticles were not cytotoxic and suitable for intravenous administration [20]. Biomimetic 
mucin modified PLGA nanoparticles were studied for the hemocompatibility and 
cytocompatibility by Thasmeen et al (2013). 1mg of modified nanoparticles incubated with 100µl 
of RBCs at 37oC showed that the RBCs exhibited favorable compatibility to both PLGA and 
modified nanoparticles [21]. Another study of PLGA nanoparticles interaction with blood 
components at 3mg/ml nanoparticle concentration showed no effects after 10 min to 24 h of 
incubation [22]. Results indicated that interactions of PLGA nanoparticles with erythrocytes did 
not induce hemolysis.  
So far, different studies regarding the interaction of PLGA nanoparticles with red blood 
cells have shown null to low hemolytic activity at low nanoparticle concentrations (up to 
10mg/ml). Our study will focus on the association of PLGA nanoparticles at different 
concentrations with red blood cells, and the effect on the RBC hemolysis at the same 
concentrations, ranging from 0.025mg/ml to 50mg/ml.   
3.2 Materials and Methods 
3.2.1 Materials and Reagents: 
 Poly (D, L –lactide-co-glycolide) acid (PLGA) polymer, poly vinyl alcohol (PVA), 
Chitosan (Chi); Fluorescein isothiocyanate (FITC), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-




diisopropylethylamine (DIPEA), and trifluoroacetic acid (TFA) were purchased from Sigma-
Aldrich (Sigma Chemical Co.Ltd., St. Louis, MO). Dichloromethane (DCM), acetone, and ethanol 
were HPLC grade and supplied by Mallinckrodt Baker (Pittsburg, NJ). Phosphate Buffered Saline 
(PBS) was purchased from ThermoFisher Scientific (Waltham, MA). Nanopure water was 
obtained using Nanopure Diamond System (Barnstead international, IA, USA). All other reagents 
and components used in this study were analytical grade.  
 The Nemesys syringe pump used for controlling the flow rate of organic and aqueous phase 
during synthesis and for flowing blood samples and nanoparticles was purchased from Dolomite 
Microfluidics (Herts, SG8 5TW, UK) and the millifluidic chip was fabricated in the J. Bennett 
Johnston Sr. Center for Advanced Microstructures & Devices (CAMD, LSU).  
3.2.2 Synthesis of Nanoparticles 
3.2.2.1 PLGA Nanoparticles 
 
 PLGA nanoparticles were synthesized by nanoprecipitation method in a millifluidic chip 
as follows. PLGA was dissolved in acetone at 20mg/ml and vortexed for 30-45 min to form the 
organic phase. A water phase consisted of a 2% PVA solution.  The organic phase and the aqueous 
phase were pumped through the channel of the millifluidic chip using the Nemesys pump. The 
sample was collected at the outlet in a vial. Next, evaporation was performed in a rotovapor (Buchi 
R-124, Buchi Analytical Inc., DE, US) for 45 min under vacuum to remove acetone. The resulting 
PLGA nanoparticle suspension was placed in the dialysis membrane and suspended in 1.5 L 
nanopure water for 48 h; the dialysis medium was changed every 8 h to remove excess surfactants. 
The suspension was frozen at -80oC for 2 h and the sample was then freeze dried, and stored at -




3.2.2.2 Silver Nanoparticles 
 Silver nanoparticles used for the comparison of hemolysis activity was prepared by 
suspending silver particles (SmartSilverTM AS from NanoHorizons, Inc. PA, USA) in PBS solution 
in a concentration of 200ppm. Further dilution were done to prepare the silver nanoparticles 
concentration of 25, 50, and 100µg/ml. 
3.2.3 Synthesis of PLGA-FITC polymer  
 PLGA was conjugated with flurorescein isothiocyanate (FITC), in order to visualize the 
attachment/interaction of the nanoparticles with blood using microscopy, and to facilitate the 
nanoparticles tracking by flow cytometry. FITC was conjugated to the terminal group of PLGA as 
follows. First of all, 1g of PLGA was dissolved in 20ml DCM at room temperature. Next, 55mg 
of HATU, 24mg of N-Boc-ethylenediamine and 0.2ml of DIPEA was added and suspension was 
stirred for 12 h at room temperature. The reaction was stopped by addition of 100 ml of distilled 
water and the solution was poured into 200ml ethanol, to obtain the precipitate of PLGA-NH-Boc. 
Next, the Boc (butyloxycarbonyl) group protecting PLGA-NH2 was removed by dissolving 900mg 
of precipitate in 15ml DCM with further addition of TFA, in 1:1 vol/vol ratio of DCM to TFA. 
The reaction was carried out for 25 min at room temperature. Then, the solution was poured into 
200ml ethanol and the white precipitate was dried out for overnight. Final step was to conjugate 
PLGA-NH2 to FITC. PLGA-NH2 polymer was dissolved in 20ml DCM containing 0.075ml 
DIPEA for 10 min. 30mg of FITC was added, and after 8 h of reaction, the organic phase was 
washed with water in a separation funnel. The organic phase was poured into 100ml ethanol to 
obtain a light yellow precipitate. The precipitate was washed six times, to remove excess untreated 
FITC. The solid precipitates were dried, under high vacuum for 30 h and kept at -20oC for further 




3.2.4 Simulated Blood Fluid (SBF) 
Simulated blood fluid (SBF) is a solution with an ion concentration close to that of human 
blood plasma, kept under mild conditions of pH and identical physiological temperature. SBF was 
prepared as described in the literature [19] by using NaCl, KCl, CaCl.H2O, KH2PO4, pyruvic acid, 
MgSO4.7H2O and sodium bicarbonate. The given electrolytes were weighed as illustrated: 6.89g 
of NaCl, 0.36g of KCl, 0.37g of CaCl.H2O, 0.29g of KH2PO4, 0.22g of pyruvic acid, 0.29g of 
MgSO4.7H2O, and 2.1g of sodium bicarbonate and then mixed into a 1 liter bottle. Then, 1 liter of 
de-ionized water was added to the bottle and stirred for 15 min. The solution was sonicated for an 
hour. HCl or NaOH solution was used to adjust the pH of the SBF to the physiological value of 
7.4. The SBF was stored in an incubator at 370C until it was used. 
3.2.5 Blood 
 Fresh blood samples used for the experiment were acquired from the rats. Louisiana State 
University – School of Medicine provided the fresh blood samples in a sodium heparin blood 
collection tube. A volume of 2-3ml of blood was obtained at a time and the blood samples were 
used within 48 h of availability. 
3.2.6 Preparation of Red Blood Cells 
For morphology, microscopy, flow cytometry and hemolysis experiments, RBCs were 
separated from other components in the fresh blood samples. A volume of 0.5ml of blood sample 
was centrifuged at 1,000 rpm for 10 min, after which the supernatant was removed. Remaining 
RBCs were washed 3 times with 2ml of Phosphate Buffer Saline (PBS), centrifuged at 1,000 rpm 




3.2.7 Particle Size and Zeta Potential Analysis 
 Freshly prepared PLGA nanoparticles were characterized by dynamic light scattering 
(DLS) using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK), to 
measure the average particle size, polydispersity index (PDI) and zeta potential. Before the 
measurements were taken, samples were diluted to a final concentration of 0.2mg/ml. DLS was 
used to characterize the nanoparticles interacted with the Simulated Blood Fluid to understand the 
effect of ions concentration, similar environmental conditions for nanoparticles in the blood, on 
the nanoparticles size. Nanoparticles were suspended in PBS at different concentrations ranging 
from 1mg/ml to 20mg/ml. Nanoparticle suspensions were added to the simulated blood fluid 1:1 
by volume and mixed for 3 min and size and PdI of the nanoparticles measured by DLS. All 
measurements were performed in triplicate. 
3.2.8 Morphology Analysis 
 JSM1400 TEM, (JEOL USA. Inc., MA, US) was used to observe the morphology of freshly 
prepared PLGA Nanoparticles and to observe red blood cells association with nanoparticles. One 
droplet of the freshly prepared PLGA-PVA nanoparticle sample was placed on a copper grid of 
400 mesh with a carbon film and the excess sample was removed with a filter paper [23].  
TEM was also used to identify changes in the morphology of red blood cells, blood exposed 
to nanoparticle suspended in PBS. For TEM analysis, 100µl of the washed RBCs was suspended 
in 700µl of PBS and 100µl of PLGA nanoparticles was added to the solution. The samples were 
placed in water bath set to 37oC for 3 h. One droplet of the solution was placed on the copper grid 
of 400 mesh. Excess sample was removed with the filter paper and uranyl acetate was used to 




3.2.9 Nanoparticle-Blood Cell Association 
3.2.9.1 Sample preparation and viewing- Scanning Electron Microscopy 
 Red blood cells washed with PBS were suspended in 1ml of PBS and 100µl of nanoparticle 
solution was added to the suspension. The samples were placed in water bath set to 37oC for 3 h 
before sample preparation for Scanning Electron Microscope (SEM). The samples were then fixed 
with 2ml solution of 8% glutaraldehyde (1ml) and 0.2M Cacodylate buffer with a pH of 7.0 for 2 
h. This was followed by rinsing with DI water for 5 min thrice. The samples were then dehydrated 
serially in 30%, 50%, 70%, 80%, 90% and 3 times in 100% ethanol. The sample preparation 
procedure was completed by drying the samples in 50%, 75% and 100% hexamethyldisilazane 
(HMDS) for 30 min. The samples were then mounted and coated with platinum and examined by 
JOEL JEM 6610LV SEM (JEOL USA. Inc., MA, US) at Socolofsky Microscopy Center, LSU. 
3.2.9.2 Flow Cytometry 
 Flow cytometry (FC) measurement was done to quantify the PLGA nanoparticles 
association with red blood cells. Before FC analysis, 0.5ml of blood was washed with 1ml of 
phosphate-buffered saline (PBS) and centrifuged at 1,000 rpm for 5 min [24]. After the supernatant 
was discarded, 100µl of the centrifuged blood was suspended in 700µl of PBS. A volume of 100µl 
of PLGA nanoparticles tagged with FITC was added and the mixture was placed in a water bath 
set to 37oC for 3 h. Next 100µl was removed and it was mixed with 1ml PBS to dilute the RBCs. 
Samples were analyzed using a Becton Dickinson FACS Aria (Becton Dickinson, San Francisco, 
CA). Dual laser flow cytometer at LSU-School of Veterinary Medicine. Approximately 100,000 
RBCs were analyzed, and a scatter plot of side scatter (SSC) versus forward scatter (FSC), side 
scatter versus fluorescence intensity of FITC and a FSC histogram was generated using FACScan 




3.2.10 Hemolytic Characterization 
 The hemolytic properties of PLGA-PVA nanoparticles were tested using the ASTM 
E2524-08 Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles [25]. 
Hemoglobin Reagent Set from Teco Diagnostics (Teco Diagnostics, Anaheim, CA, US) was used. 
First, hemoglobin standards were made covering a range of concentrations of 1-150mg/ml and a 
standard curve was generated. Blood was diluted in PBS (+Ca2+/Mg2+) to a hemoglobin 
concentration of 10mg/ml. In a test tube, 700µl of PBS, 100µl of diluted blood and 100µl of PLGA-
PVA nanoparticle were mixed and placed on an orbital shaker for 30min. The samples were then 
placed in a water bath set to 37oC for 3 h. Next, samples were centrifuged for 15 min at 800g and 
the supernatant was collected. Then, 100µl of supernatant was added to a 96 well plate along with 
100µl of cyanmethemoglobin reagent. The mixture was covered, gently shaken and allowed to 
react for 10min; then, its absorbance at 540nm was measured on a Perkin Elmer Wallac Victor2 
plate reader (Waltham, MA, US). This absorbance was compared to the standard curve to 
determine hemoglobin concentration. Hemoglobin concentration was divided by the hemoglobin 
concentration of the diluted blood solution to quantify percent hemolysis as described by the 
equation: 
% 𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =  
𝐻𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝐻𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑏𝑙𝑜𝑜𝑑
 × 100 
Cells exposed to a 10% Triton X solution were used as the positive control. All measurements 
were performed in triplicate and known standards were run with each sample to ensure they 
correlated properly with the standard curve.  
3.2.11 Statistics 
 Statistical Analysis was conducted using JMP Pro 12 software (SAS Campus Drive, NC, 




statistical differences between groups were judged to be significant at p-value < 0.05 after analysis 
of variance. All the results are expressed as mean ± standard deviation.  
3.3 Results and Discussions 
3.3.1 Particle Characterization 
 PLGA in PBS and PLGA nanoparticles in SBF were 184nm and in the range of 140 – 
195nm in diameter respectively (Table 3.1). The final concentration of PLGA nanoparticles in 
SBF was maintained at 0.1mg/ml and 1mg/ml. Polydispersity index (PdI) ranged from 0.14 for 
PLGA nanoparticles suspended in PBS to 0.256 for PLGA Nanoparticles in SBF at 0.1mg/ml.  
PLGA nanoparticles were positively charged (2.37mV in SBF and 1.00mV in PBS). The increment 
in size of PLGA nanoparticles (10nm) and small decrease in zeta potential (1mV) at the higher 
concentration (1mg/ml) was attributed to the adsorption of cations from SBF onto the particles. 





PDI Zeta Potential 
(mV) 
PLGA (PBS) 0.1 mg/ml 184.0±1.14 0.136±0.023  + 2.37±0.599 
PLGA (SBF) 0.1 mg/ml 144.1±12.17 0.256±0.102 + 1.78±0.625 
PLGA (SBF) 1 mg/ml 194.7±0.2 0.109±0.005 + 1.01±0.485 
 
3.3.2 TEM Analysis 
The RBCs analyzed by TEM showed a spherical shape with a diameter in the range of 5µm 
to 7µm (Figure 3.1a). RBCs interaction with nanoparticles was also analyzed by TEM. TEM 
pictures of the RBCs exposed to nanoparticles showed nanoparticles of different size in the 
background, around the blood cells, as well as on the surface of the cells (Figure 3.1b) At high 






b.   c.  
Figure 3.1:  TEM image of untreated red blood cell (a), treated red blood cell with nanoparticles 
on the surface of cell shown by the arrow (b), and RBCs under crenation phase in presence of 
nanoparticles on the surface of cell shown by the arrow (c) 
 
3.3.3 SEM Analysis 
 To obtain more information about the localization of nanoparticles on the surface of RBCs, 
SEM analysis was used. RBCs were incubated with PLGA nanoparticles at nanoparticles 
concentrations ranging from 2mg/ml to 50mg/ml of blood for 3 h. Particles of 200nm were found 
on the surface of treated RBCs (Figure 3.2). Figure 3.2c, c’ and Figure 3.2b, b’ showed the 
presence of nanoparticles (white) on the surface of RBCs for all the treated samples with some 
evident agglomeration. Small pores were also evident on the surface of the RBCs, most likely 
induced by the surfactant, PVA. Crenated cells and particle agglomeration on the surface of cells 
were more prevalent in the RBCs treated with high concentrations of nanoparticles (Figures 3.2d, 
























Figure 3.2: SEM images of RBCs (a) and RBCs treated with nanoparticles at different 
concentrations at lower magnification; 2mg/ml (b), 3mg/ml (c), 10mg/ml (d) and 50mg/ml (e) 
and at higher magnification, same concentrations (b’, c’, d’, e’). Particles of 200nm and 
deformed cells are evident in the higher concentration treated samples. Bigger agglomerates are 
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agglomerates were observed at the highest nanoparticle concentration of 50mg/ml blood.  Bigger 
pore sizes were also evident on the surface of the RBCs at this excessive concentration (Figures 
3.2e, e’). The change in RBCs in terms of morphology (from biconcave disc-shaped to round) and 
size (from 7µm to 3-4µm) observed in the SEM pictures (Figure 3.2) was due to the sample 
preparation followed prior to SEM analysis. The samples were chemically fixed with aldehydes, 
dried by alcohol and then sputtered using platinum which lead to shrinkage of the cells and change 
in size of the blood cells [26]. 
3.3.4 Nanoparticles-RBC association - Flow Cytometry Analysis 
 Flow cytometry analysis showed that PLGA nanoparticles interaction with RBCs was 
concentration dependent, as indicated by the Side Scatter (SSC) and intensity of FITC change upon 
exposure of RBCs to PLGA nanoparticles (Figure 3.3).  
a.   b.   c. 
d.  e.    f. 
g.   h.  
Figure 3.3: Representative FITC intensity histograms of the blood samples exposed to PLGA 
nanoparticles at different concentrations, as follows: untreated blood (a) and blood exposed to 
nanoparticles at 2mg/ml (b), 3mg/ml (c), 5mg/ml (d), 8mg/ml (e), 10mg/ml (f), 20mg/ml (g), and 




When RBCs were treated with higher concentration of nanoparticles, more nanoparticles 
were attached to the surface of the RBCs (Figure 3.3). The intensity of light emitted by RBCs 
shifted to the area with FITC-specific signal; the shift was more pronounced with increasing 
concentration of nanoparticles. For the highest concentration 50mg/ml (Figure 3.3h), intensity 
peak was completely in the FITC region. 
For 100,000 cells counted in each experiment, only 0.22% gave a fluorescence signal for 
control (blood without nanoparticles) whereas 13.95%, 17.41%, 23.32%, 29.92%, 37.21%, 
49.71% and 73.46% blood cells had a signal in the FITC- specific fluorescence section when 
exposed to increasing concentrations of nanoparticles of 2mg/ml, 3mg/ml, 5mg/ml, 8mg/ml, 
10mg/ml, 20mg/ml and 50mg/ml, respectively. Blood cells exposed to 20mg/ml and 50mg/ml 
nanoparticle concentration had the highest fluorescence intensity (Figure 3.4). Statistically, all the 
samples were significantly different from each other (p< 0.05). 
 
Figure 3.4: FACS analysis of nanoparticles associated with rat blood cells exposed to increasing 
concentrations of PLGA nanoparticles. Untreated blood sample was used as the negative control. 




3.3.5 Hemolytic Assay  
 PLGA Nanoparticles in contact with diluted human blood for 3 h 15 min induced 
hemolysis, detected as increased intensity with the concentration of nanoparticles in the PBS/blood 
mixture (Figure 3.5). Nanoparticles samples at the highest concentrations (20 and 50mg/ml) 
caused a significantly higher level of hemolysis than the negative control. 
 
Figure 3.5. In vitro hemolysis of rat blood exposed to different concentrations of PLGA 
Nanoparticles. Untreated blood sample was used as the negative control (-) and Triton X-10 % 
treated blood was used as the positive control (+). Different letters indicate significant difference 
between samples (p-value < 0.05 for concentrations higher than 10mg/ml and p-value > 0.05 for 
concentrations lower than 10mg/ml).  
Non-treated blood samples (negative control) showed nearly 16% hemolysis due to simple 
handling and sample preparation. Taking the negative control as a baseline, nanoparticles at 
2mg/ml, 3mg/ml, 5mg/ml, 8mg/ml and 10mg/ml concentration did not induce any significant 
hemolysis in the diluted blood exposed to the nanoparticles, whereas at 20mg/ml and 50mg/ml 
nanoparticles caused an increased in the hemolysis by 6% to 20%, respectively. The highest 




significantly different from the negative control (Figure 3.4). According to the hemolysis criterion 
in ASTM E2524-08 standard, an increase in the percent hemolysis by more than 5% indicates 
damage to RBCs caused by the test materials [27]. Considering the baseline for the hemolysis due 
to sample handling and preparation, the criteria in ASTM E2524-08 standard was not exceeded at 
smaller PLGA nanoparticle concentration (2, 3, 5, 8 and 10mg/ml). PLGA nanoparticles at higher 
concentrations of 20mg/ml and 50mg/ml exceeded the criteria.  
 For all of the experiments rat blood was used. A typical male rat weighs 300-500g and have 
a blood volume of 50-70ml/kg [28]. Depending upon the weight of the rat, they will have 15-35ml 
of blood, so, the higher concentration (10, 20 and 50mg/ml) of the nanoparticles stated on this 
work is equivalent to 150mg to 1,500mg/dose injected nanoparticles. In people, the dose would 
translate to 10.7g/dose even at the lowest concentration (2mg/ml) tested, for an average man of 70 
kg. Such high concentrations are too high to be relevant for biomedical applications, but the data 
is important in understanding the dose effect of PLGA nanoparticles on RBCs.  
Silver particles were used for the comparison of hemolytic activity against PLGA 
nanoparticles [28]. Different concentrations of Ag NP suspension (25, 50, 100, 200µg/ml) were 
prepared. PLGA NP suspension was prepared in the same concentration. Ag nanoparticles induced 
significant hemolysis to the diluted blood samples. Hemolysis induced was up to 40.07% for 
200µg/ml concentration and for 25µg/ml Ag nanoparticle concentration, hemolysis was 26.96% 
(Figure 3.6). Hemolysis induced by the Ag NP at all concentrations (25, 50, 100 and 200µg/ml) 
tested was significantly different than that of the negative control, and exceeded the hemolysis 
criterion. PLGA nanoparticles at 25µg/ml, 50µg/ml, 100µg/ml, and 200µg/ml concentration did 




(%) was induced at 200µg/ml concentration Ag nanoparticles (Figure 3.6) as it was induced at 250 
time higher concentration of PLGA Nanoparticles (Figure 3.5). 
 
Figure 3.6. In vitro hemolysis of rat blood exposed to different concentrations of PLGA and Ag 
Nanoparticles. Untreated blood sample was used as negative control (-) and Triton X-10% treated 
blood was used as the positive control (+). Different letters indicate significant difference between 
samples (p-value < 0.05 for Ag samples and p-value > 0.05 for PLGA Nanoparticles) 
 
3.4 Conclusions  
 In an effort to study the interaction of particles with red blood cells, TEM and SEM imaging 
and flow cytometry experiments were performed. Results from flow cytometry analysis indicated 
that NP-RBCs interaction was concentration-dependent. The data obtained suggested that 
association of nanoparticles with RBCs was statistically different for all concentration tested, but 
only at high concentrations, exceeding 20mg/ml blood, nanoparticles caused hemolysis of RBCs. 
Comparison between the of Ag nanoparticle and PLGA nanoparticles treated RBCs showed that 
concentration of PLGA nanoparticles can be increased by 250 times relative to Ag nanoparticles 




PLGA nanoparticles caused null to minimal damage to red blood cells at low concentrations 
expected to be employed for biomedical applications.  
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CHAPTER 4. CONCLUSIONS AND FUTURE WORKS 
4.1 Conclusions 
 A nanoprecipitation method was developed and optimized to synthesize PLGA 
nanoparticles in a millifluidic chip. Synthesis of PLGA nanoparticles of average size 220nm and 
narrow size distribution similar to those made by a bulk nanoprecipitation method was possible by 
manipulation of the flow rate of the aqueous phase and the flow rate ratio of aqueous:organic 
phase. It was concluded that millifluidic chip could be used for the synthesis of uniform sized 
particles. Manipulation of flow rate and FRR can further help in the synthesis of narrow size 
distributed smaller particles. The millifluidic chip provided the advantage of control of flow rate, 
ratio of aqueous phase to organic phase and mixing of the solutions for the synthesis of particles. 
PLGA nanoparticles made with the millifluidic chip were dialyzed and freeze dried to be used in 
the second part of the study for the interaction with blood cells. 
 Experimental investigation of interaction of PLGA nanoparticles with blood cells 
suggested that PLGA nanoparticles associated with the surface of RBCs, but had no hemotoxic 
effect at concentration lower than 20mg/ml. At concentration higher than 20mg/ml, PLGA 
nanoparticles showed significant hemolytic activity, but the dose equivalent to this high 
concentration of nanoparticles exceeds by a wide margin and is not representative to doses likely 
used in biomedical applications.  
 4.2 Future work 
 Millifluidic chip was used to synthesize the PLGA nanoparticles. Only two different 
organic solvents: acetonitrile and acetone were used as organic phase and only one surfactant, 
PVA was used as a surfactant. Further studies can be conducted on use of different surfactants and 




synthesize various nanoparticles under different conditions. Effects of higher flow rate than those 
employed in this study can be studied to confirm that even smaller and more uniform particles can 
be formed at higher flow rate in millifluidic chips. Further, research work can be focused on 
millifluidic chip to study the formation of nanoparticles and visualize the nanoparticles within the 
chip. 
 In this study, the interaction of nanoparticles and blood cells was studied by exposing RBCs 
to fluorescently tagged nanoparticles for a certain period. In this experimental approach 
nanoparticles were stabilized by PVA as surfactant. Further studies can be conducted with different 
surfactants to understand the impact of different nanoparticle surfaces on the RBCs. Research can 
be conducted to study how the nanoparticles have adhered, internalized and affected the RBCs. 
Further studies can be focused on use of millifluidic chip to look at the time-dependent interaction 





A.1 PLGA NANOPARTICLES SYNTHESIS 
 
2.1 Size of PLGA nanoparticles: PLGA nanoparticles were synthesized at different flow rate and 
flow rate ratio for acetonitrile as the organic phase. DLS was used for the characterization of the 
nanoparticles prepared 
 
 Bulk  
Millifluidics (aqueous phase flow rate) 
600µl/min 800µl/min 1000µl/min 
Ratio 
(aqueous to 
organic) Size(nm) PDI Size(nm) PDI Size(nm) PDI Size(nm) PDI 
10:1 202.4 0.089 289.7 0.136 285.9 0.237 282.7 0.231 
20:1 204.5 0.094 290.6 0.221 273.4 0.244 271.4 0.228 
30:1 199.4 0.083 270.2 0.256 268.5 0.256 239.5 0.146 
40:1 204.1 0.188 265.7 0.241 257.7 0.234 229.6 0.192 
 
2.2 Size of PLGA Nanoparticles: PLGA nanoparticles synthesized at different flow rate and flow 




Millifluidics (aqueous phase flow rate) 
 600µl/min 800µl/min 1000µl/min 
Ratio 
(aqueous to 
organic) Size(nm) PDI Size(nm) PDI Size(nm) PDI Size(nm) PDI 
10 198.4 0.086 266.7 0.195 269.1 0.243 252.8 0.215 
20 197 0.089 250.4 0.197 255.3 0.155 241.7 0.092 
30 194 0.138 243.3 0.163 240.2 0.143 235.1 0.183 
40 205.4 0.172 238.4 0.254 236.7 0.182 217.7 0.221 
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APPENDIX 
A.2 INTERACTION OF PLGA NANOPARTICLES WITH RED BLOOD CELLS
3.4 Flow cytometry 
PLGA nanoparticles association with RBCs was studied by flow cytometry quantitatively. 
Different concentration (mg/ml) of fluorescently tagged Nanoparticles were interacted with RBCs. 
Number of RBCs tagged with nanoparticles were counted. Percentage of RBCs with nanoparticles 


















1 0.25 14.34 16.78 23.34 29.95 36.76 50.02 72.95 
2 0.18 13.83 18.18 23.3 30 37.43 49.6 73.78 
3 0.24 13.69 17.28 23.33 29.8 37.45 49.5 73.65 
Average 0.22 13.95 17.41 23.32 29.92 37.21 49.71 73.46 
Std 0.04 0.34 0.71 0.02 0.10 0.39 0.28 0.45 
Statistical Analysis was done by JMP pro 12 software. 




Connecting Letters Report 
Level Mean 
50mg/ml A  73.460000 
20mg/ml  B  49.706667 
10mg/ml   C  37.213333 
8mg/ml    D  29.916667 
5mg/ml     E  23.323333 
3mg/ml      F 17.413333 
2mg/ml G 13.953333 
Negative  H 0.223333 
Ordered Differences Report 
Level  - Level Difference Std Err Dif Lower CL Upper CL p-Value
50mg/ml Negative 73.23667 0.2975922 72.20636 74.26698 <.0001* 
50mg/ml 2mg/ml 59.50667 0.2975922 58.47636 60.53698 <.0001* 
50mg/ml 3mg/ml 56.04667 0.2975922 55.01636 57.07698 <.0001* 
50mg/ml 5mg/ml 50.13667 0.2975922 49.10636 51.16698 <.0001* 
20mg/ml Negative 49.48333 0.2975922 48.45302 50.51364 <.0001* 
50mg/ml 8mg/ml 43.54333 0.2975922 42.51302 44.57364 <.0001* 
10mg/ml Negative 36.99000 0.2975922 35.95969 38.02031 <.0001* 
50mg/ml 10mg/ml 36.24667 0.2975922 35.21636 37.27698 <.0001* 
20mg/ml 2mg/ml 35.75333 0.2975922 34.72302 36.78364 <.0001* 
20mg/ml 3mg/ml 32.29333 0.2975922 31.26302 33.32364 <.0001* 




Level  - Level Difference Std Err Dif Lower CL Upper CL p-Value  
20mg/ml 5mg/ml 26.38333 0.2975922 25.35302 27.41364 <.0001*  
50mg/ml 20mg/ml 23.75333 0.2975922 22.72302 24.78364 <.0001*  
10mg/ml 2mg/ml 23.26000 0.2975922 22.22969 24.29031 <.0001*  
5mg/ml Negative 23.10000 0.2975922 22.06969 24.13031 <.0001*  
10mg/ml 3mg/ml 19.80000 0.2975922 18.76969 20.83031 <.0001*  
20mg/ml 8mg/ml 19.79000 0.2975922 18.75969 20.82031 <.0001*  
3mg/ml Negative 17.19000 0.2975922 16.15969 18.22031 <.0001*  
8mg/ml 2mg/ml 15.96333 0.2975922 14.93302 16.99364 <.0001*  
10mg/ml 5mg/ml 13.89000 0.2975922 12.85969 14.92031 <.0001*  
2mg/ml Negative 13.73000 0.2975922 12.69969 14.76031 <.0001*  
8mg/ml 3mg/ml 12.50333 0.2975922 11.47302 13.53364 <.0001*  
20mg/ml 10mg/ml 12.49333 0.2975922 11.46302 13.52364 <.0001*  
5mg/ml 2mg/ml 9.37000 0.2975922 8.33969 10.40031 <.0001*  
10mg/ml 8mg/ml 7.29667 0.2975922 6.26636 8.32698 <.0001*  
8mg/ml 5mg/ml 6.59333 0.2975922 5.56302 7.62364 <.0001*  
5mg/ml 3mg/ml 5.91000 0.2975922 4.87969 6.94031 <.0001*  






















3.5 Hemolytic Assay Standard Curve: All hemolytic percentage were calculated using a standard 
curve. The absorbance was measured on Perkin Elmer Wallac Victor2 plate reader (Waltham, MA, 





3.5 Hemolytic Assay for PLGA Nanoparticles: Concentration of Hemoglobin (g/dl) and hemolysis 









2 2.30 17.26 
3 2.16 16.22 
5 2.35 17.65 
8 2.36 17.78 
10 2.47 18.56 
20 2.99 22.45 
50 4.71 35.43 
Negative control 2.23 16.74 
Positive Control 12.57 94.48 
 
Statistical Analysis was done by JMP pro 12 software.  




Level       Mean 
Positive A      94.480000 























50mg/ml  B     35.430000 
20mg/ml   C    22.450000 
10mg/ml    D   18.560000 
8mg/ml    D E  17.780000 
5mg/ml    D E  17.650000 
2mg/ml    D E  17.260000 
Negative    D E  16.740000 
3mg/ml     E  16.220000 
Levels not connected by same letter are significantly different. 
Orders differences report 
 
Level  - Level Difference Std Err Dif Lower CL Upper CL p-Value  
Positive 3mg/ml 78.26000 0.5235987 76.4254 80.09462 <.0001*  
Positive Negative 77.74000 0.5235987 75.9054 79.57462 <.0001*  
Positive 2mg/ml 77.22000 0.5235987 75.3854 79.05462 <.0001*  
Positive 5mg/ml 76.83000 0.5235987 74.9954 78.66462 <.0001*  
Positive 8mg/ml 76.70000 0.5235987 74.8654 78.53462 <.0001*  
Positive 10mg/ml 75.92000 0.5235987 74.0854 77.75462 <.0001*  
Positive 20mg/ml 72.03000 0.5235987 70.1954 73.86462 <.0001*  
Positive 50mg/ml 59.05000 0.5235987 57.2154 60.88462 <.0001*  
50mg/ml 3mg/ml 19.21000 0.5235987 17.3754 21.04462 <.0001*  
50mg/ml Negative 18.69000 0.5235987 16.8554 20.52462 <.0001*  
50mg/ml 2mg/ml 18.17000 0.5235987 16.3354 20.00462 <.0001*  
50mg/ml 5mg/ml 17.78000 0.5235987 15.9454 19.61462 <.0001*  
50mg/ml 8mg/ml 17.65000 0.5235987 15.8154 19.48462 <.0001*  
50mg/ml 10mg/ml 16.87000 0.5235987 15.0354 18.70462 <.0001*  
50mg/ml 20mg/ml 12.98000 0.5235987 11.1454 14.81462 <.0001*  
20mg/ml 3mg/ml 6.23000 0.5235987 4.3954 8.06462 <.0001*  
20mg/ml Negative 5.71000 0.5235987 3.8754 7.54462 <.0001*  
20mg/ml 2mg/ml 5.19000 0.5235987 3.3554 7.02462 <.0001*  
20mg/ml 5mg/ml 4.80000 0.5235987 2.9654 6.63462 <.0001*  
20mg/ml 8mg/ml 4.67000 0.5235987 2.8354 6.50462 <.0001*  
20mg/ml 10mg/ml 3.89000 0.5235987 2.0554 5.72462 <.0001*  
10mg/ml 3mg/ml 2.34000 0.5235987 0.5054 4.17462 0.0070*  
10mg/ml Negative 1.82000 0.5235987  -0.0146 3.65462 0.0528  
8mg/ml 3mg/ml 1.56000 0.5235987  -0.2746 3.39462 0.1335  
5mg/ml 3mg/ml 1.43000 0.5235987  -0.4046 3.26462 0.2042  
10mg/ml 2mg/ml 1.30000 0.5235987  -0.5346 3.13462 0.3015  
8mg/ml Negative 1.04000 0.5235987  -0.7946 2.87462 0.5700  
2mg/ml 3mg/ml 1.04000 0.5235987  -0.7946 2.87462 0.5700  
5mg/ml Negative 0.91000 0.5235987  -0.9246 2.74462 0.7179  
10mg/ml 5mg/ml 0.91000 0.5235987  -0.9246 2.74462 0.7179  
10mg/ml 8mg/ml 0.78000 0.5235987  -1.0546 2.61462 0.8464  
2mg/ml Negative 0.52000 0.5235987  -1.3146 2.35462 0.9818  
8mg/ml 2mg/ml 0.52000 0.5235987  -1.3146 2.35462 0.9818  
Negative 3mg/ml 0.52000 0.5235987  -1.3146 2.35462 0.9818  
5mg/ml 2mg/ml 0.39000 0.5235987  -1.4446 2.22462 0.9972  







3.5 Comparison of Hemolysis for PLGA and Ag Nanoparticles: Concentration of Hemoglobin 
(g/dl) and hemolysis percentage (%) caused by different concentration of PLGA nanoparticles 
(µg/ml), Silver nanoparticles (µg/ml), controls 
 
Conc. PLGA  Ag Controls 
NC   18.02 
25 18.30 26.96  
50 17.97 27.02  
100 18.24 37.66  
200 19.99 40.07  
PC   97.55 
 





Level       Mean 
Positive A      97.552333 
0.2s  B     40.073667 
0.1s  B     37.656000 
0.05s   C    27.023333 
0.025s   C    26.962667 
0.2p    D   19.992667 
0.025p    D   18.299000 
0.1p    D   18.243667 
Negative    D   18.017667 
0.05p    D   17.966667 
Levels not connected by same letter are significantly different. 
Orders differences report 
Level  - Level Difference Std Err Dif Lower CL Upper CL p-Value  
Positive 0.05p 79.58567 0.8186404 76.6868 82.48456 <.0001*  
Positive Negative 79.53467 0.8186404 76.6358 82.43356 <.0001*  
Positive 0.1p 79.30867 0.8186404 76.4098 82.20756 <.0001*  
Positive 0.025p 79.25333 0.8186404 76.3544 82.15223 <.0001*  
Positive 0.2p 77.55967 0.8186404 74.6608 80.45856 <.0001*  
Positive 0.025s 70.58967 0.8186404 67.6908 73.48856 <.0001*  
Positive 0.05s 70.52900 0.8186404 67.6301 73.42789 <.0001*  
Positive 0.1s 59.89633 0.8186404 56.9974 62.79523 <.0001*  
Positive 0.2s 57.47867 0.8186404 54.5798 60.37756 <.0001*  
0.2s 0.05p 22.10700 0.8186404 19.2081 25.00589 <.0001*  
0.2s Negative 22.05600 0.8186404 19.1571 24.95489 <.0001*  
0.2s 0.1p 21.83000 0.8186404 18.9311 24.72889 <.0001*  
0.2s 0.025p 21.77467 0.8186404 18.8758 24.67356 <.0001*  
0.2s 0.2p 20.08100 0.8186404 17.1821 22.97989 <.0001*  
0.1s 0.05p 19.68933 0.8186404 16.7904 22.58823 <.0001*  
0.1s Negative 19.63833 0.8186404 16.7394 22.53723 <.0001*  
0.1s 0.1p 19.41233 0.8186404 16.5134 22.31123 <.0001*  
0.1s 0.025p 19.35700 0.8186404 16.4581 22.25589 <.0001*  
0.1s 0.2p 17.66333 0.8186404 14.7644 20.56223 <.0001*  




Level  - Level Difference Std Err Dif Lower CL Upper CL p-Value  
0.2s 0.05s 13.05033 0.8186404 10.1514 15.94923 <.0001*  
0.1s 0.025s 10.69333 0.8186404 7.7944 13.59223 <.0001*  
0.1s 0.05s 10.63267 0.8186404 7.7338 13.53156 <.0001*  
0.05s 0.05p 9.05667 0.8186404 6.1578 11.95556 <.0001*  
0.05s Negative 9.00567 0.8186404 6.1068 11.90456 <.0001*  
0.025s 0.05p 8.99600 0.8186404 6.0971 11.89489 <.0001*  
0.025s Negative 8.94500 0.8186404 6.0461 11.84389 <.0001*  
0.05s 0.1p 8.77967 0.8186404 5.8808 11.67856 <.0001*  
0.05s 0.025p 8.72433 0.8186404 5.8254 11.62323 <.0001*  
0.025s 0.1p 8.71900 0.8186404 5.8201 11.61789 <.0001*  
0.025s 0.025p 8.66367 0.8186404 5.7648 11.56256 <.0001*  
0.05s 0.2p 7.03067 0.8186404 4.1318 9.92956 <.0001*  
0.025s 0.2p 6.97000 0.8186404 4.0711 9.86889 <.0001*  
0.2s 0.1s 2.41767 0.8186404  -0.4812 5.31656 0.1544  
0.2p 0.05p 2.02600 0.8186404  -0.8729 4.92489 0.3371  
0.2p Negative 1.97500 0.8186404  -0.9239 4.87389 0.3686  
0.2p 0.1p 1.74900 0.8186404  -1.1499 4.64789 0.5251  
0.2p 0.025p 1.69367 0.8186404  -1.2052 4.59256 0.5662  
0.025p 0.05p 0.33233 0.8186404  -2.5666 3.23123 1.0000  
0.025p Negative 0.28133 0.8186404  -2.6176 3.18023 1.0000  
0.1p 0.05p 0.27700 0.8186404  -2.6219 3.17589 1.0000  
0.1p Negative 0.22600 0.8186404  -2.6729 3.12489 1.0000  
0.05s 0.025s 0.06067 0.8186404  -2.8382 2.95956 1.0000  
0.025p 0.1p 0.05533 0.8186404  -2.8436 2.95423 1.0000  
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